BioSpace News Archive

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the quarter ended September 30, 2020.

DaVita Inc. (NYSE: DVA) announced financial and operating results for the third quarter ended September 30, 2020.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its gastroenterology business, Salix Pharmaceuticals (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to rifaximin for the treatment of sickle cell disease

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 5, 2020 . AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) on Nov

Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2021 ended September 30, 2020.

-Net Product Sales $267.5 Million in 3Q20, an Increase of 60 Percent Over 3Q19- -Collaborations with Merck for Ladiratuzumab Vedotin and TUKYSA; Seagen Received $725M in Upfront Payments and $1B Equity Investment- -Positive Data from Two PADCEV Clinical Trials to Support Global Registration Applications and Expand U.S. Indication- -Positive Data from Tisotumab Vedotin Pivotal Trial; BLA Planned to Support U.S. Accelerated Approval-

ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended September 30, 2020.

Blue Water Vaccines, Inc., announced today that the Company is accelerating the development of a new vaccine candidate to combat the potential pandemic influenza strain, G4 EA H1N1, which was identified by scientists in China in the summer of 2020

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020. The company hosted a conference call on October 13, 2020, in conjunction with reporting preliminary third-quarter net sales. A replay of that call is available on Flexion’s corporate website: https://ir.flexiont h erapeutics.com/events-and-pres

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced plans to report third quarter 2020 financial results on Monday, November 9, 2020, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. A